<DOC>
	<DOCNO>NCT00005876</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness nitrocamptothecin treat patient locally advance metastatic stomach cancer remove surgery .</brief_summary>
	<brief_title>Nitrocamptothecin Treating Patients With Locally Advanced Metastatic Stomach Cancer That Can Be Removed During Surgery</brief_title>
	<detailed_description>OBJECTIVES : I . Determine objective response rate , progression-free survival , overall survival , time treatment failure patient unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction treat oral nitrocamptothecin . II . Determine toxicity regimen patient . OUTLINE : Patients stratify accord prior therapy ( yes v ) . Patients receive oral nitrocamptothecin day 1-5 . Treatment repeat every week 8 course absence disease progression unacceptable toxicity . Patients stable respond disease week 8 may receive additional course therapy . Patients follow every 3 month death . PROJECTED ACCRUAL : Approximately 21-55 patient accrue study .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unresectable locally advanced metastatic adenocarcinoma stomach gastroesophageal junction Limited prior immunotherapy chemotherapy OR Failure 1 prior regimen immunotherapy chemotherapy ( include chemotherapy radiosensitizer ) Primarily resistant responsive disease subsequent progression No osseous metastasis site disease Bidimensionally measurable evaluable disease Mediastinal hilar lymph node must least 1.5 cm diameter CT MRI scan consider measurable No brain metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 OR Karnofsky 80100 % Life expectancy : At least 12 week Hematopoietic : Absolute granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.5 mg/dL No Gilbert 's syndrome Renal : Creatinine great 1.5 mg/dL Calcium great 12 mg/dL OR No symptomatic hypercalcemia treatment Cardiovascular : No New York Heart Association class III IV heart disease No angina , myocardial infarction , congestive heart failure within past 6 month Gastrointestinal : No intestinal obstruction No diarrhea ( great 4 loose stool per day ) Able swallow Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection nonmalignant medical illness uncontrolled control may jeopardize complication study therapy No history seizures No psychiatric disorder would preclude compliance No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix No preexisting cystitis PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent immunotherapy include filgrastim ( GCSF ) Chemotherapy : See Disease Characteristics No prior topoisomerase I inhibitor ( e.g. , irinotecan , topotecan , aminocamptothecin ) At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy Radiotherapy : No prior radiotherapy major bone marrowcontaining area ( e.g. , pelvis , lumbar spine ) No prior radiotherapy sole indicator lesion At least 4 week since prior limit radiotherapy recover No concurrent radiotherapy Surgery : At least 1 week since prior minor surgery recover At least 3 week since prior major surgery recover Other : No concurrent phenytoin , phenobarbital , antiepileptic prophylaxis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>